



## **Bibliography on the Ethical, Legal, and Social Implications (ELSI) of Advanced Biopreservation Technologies (2000-2022)**

*Last revised: August 7, 2022*

Prepared by Claire Colby, JD Candidate, University of Minnesota Law School, working with Professors Susan M. Wolf and Timothy L. Pruett; Revised by Michael Van Ryn, JD Candidate, University of Minnesota Law School

**Introduction:** This bibliography contains resources on the ethical, legal, and social implications (ELSI) of advanced biopreservation. The bibliography also includes information about ethical frameworks used to analyze emerging technology. Because this advanced biopreservation technology remains in early stages of development, dedicated ELSI literature about specific envisioned applications of this technology is relatively scarce. This bibliography includes that literature and provides resources for ELSI issues relevant to the various use cases. This document centers on ELSI issues and does not seek to replicate the full scientific literature for each application area. As such, the bibliography generally features articles that reference ELSI issues and excludes more technical resources. This bibliography is **limited to sources published in or after the year 2000**, and sources published in English.

This bibliography was prepared as work for ATP-Bio. ATP-Bio is an NSF Engineering Research Center (ERC) supported by grant no. EEC 1941543. ATP-Bio is co-led by the University of Minnesota's Institute for Engineering in Medicine and Massachusetts General Hospital's Center for Engineering in Medicine and Surgery. More information about ATP-Bio can be found [here](#). To suggest additional resources for this bibliography, please email Consortium on Law and Values Senior Administrative Director Dori Henderson at [hend0054@umn.edu](mailto:hend0054@umn.edu).

This bibliography is organized into **eight topical areas**. Readers may navigate to each section and subsection by clicking the corresponding text in the Table of Contents. Within each subsection, entries are listed alphabetically by the first author or for full books, by editor. For subsections with multiple articles from a single author, these resources are then further organized by year. Many of the resources contained in this bibliography could be cross-listed in multiple sections, but each is listed only once.

**Sources added since the previous iteration of this bibliography (March 22, 2022) are marked with an asterisk (\*) at the beginning of the source.**



## Table of Contents

I. Ethics and Policy Issues Raised by Advanced Biopreservation	3
II. Guidance for Responsible Innovation	4
A. Responsible Innovation/Risk Innovation	4
B. Anticipatory Governance/Governance of Emerging Technologies	5
C. Ethical Innovation in Nanotechnology	5
D. Public Opinion on Emerging Technologies	7
III. Organ Transplantation	7
A. Ethics and Regulatory Sources	7
B. Applications -- ELSI issues	7
1. Commercialization, Exploitation, and Trafficking	7
2. Equitable Allocation of Organs	8
3. Human Testing of Manipulated Organs	9
IV. Cells, Tissues, and Other Medical Products of Human Origin	10
A. Ethics and Regulatory Sources	10
B. Applications -- ELSI Issues	11
1. Biobanking	11
2. Production and Scaling Up of Cell Therapies	12
V. Microphysiological Systems and Organoids	13
A. Ethics and Regulatory Sources	13
B. Applications -- ELSI Issues	14
VI. Whole Organisms	14
A. Model Organisms	14
1. Ethics and Regulatory Sources	14
2. Applications --ELSI Issues	15
B. Pathogens	15



1. Ethics and Regulatory Sources	15
2. Applications--ELSI Issues	16
VII. Environmental Uses	16
A. Ethics and Regulatory Sources	16
B. Applications -- ELSI Issues	18
1. Biorepositories to Protect Biodiversity	18
2. Combining Advanced Biopreservation with Other Technologies (Like De-Extinction or Gene Drive Technology)	19
VIII. Aquaculture & Food Production	19
A. Ethics and Regulatory Sources	19
B. Applications -- ELSI Issues	20

#### **I. Ethics and Policy Issues Raised by Advanced Biopreservation**

Boers S, van Delden JJM, Clevers H, Bredenoord AL. Organoid Biobanking: Identifying the Ethics. *EMBO Reports* 2016;17:938-941. [Link](#).

Bojic S, Murray A, Bentley BL, Spindler R, Pawlik P, Cordeiro JL, Bauer R, de Magalhaes JP. Winter Is Coming: The Future of Cryopreservation. *BMC Biology* 2021;19. doi: [10.1186/s12915-021-00976-8](https://doi.org/10.1186/s12915-021-00976-8). [Link](#).

\*de Jongh D, Massey EK, the VANGUARD consortium, Bunnik EM. Organoids: A Systematic Review of Ethical Issues. *Stem Cell Research & Therapy* 2022;13:337. [Link](#).

Giwa S, Lewis JK, Alvarez L, Langer R, Roth AE, Church GM, Markmann JF, Sachs DH, Chandraker A, Wertheim JA, Rothblatt M, Boyden ES, Eidbo E, Lee WPA, Pomahac B, Brandacher G, Weinstock DM, Elliott G, Nelson D, Acker JP, Uygun K, Boris Schmalz, Weegman BP, Tocchio A, Fahy GM, Storey KB, Rubinsky B, Bischof J, Elliott JAW, Woodruff TK, Morris GJ, Demirci U, Brockbank KGM, Woods EJ, Ben RN, Baust JG, Gao D, Fuller B, Rabin Y, Kravitz DC, Taylor MJ, Toner M. The Promise of Organ and Tissue Preservation to Transform Medicine. *Nature Biotechnology* 2017;35:530-542. [Link](#).

Hagedorn M, Carter VL. Cryobiology: Principles, Species Conservation and Benefits for Coral Reefs. *Reproduction, Fertility, and Development* 2016;28:1049-1060. [Link](#).

Hagedorn M, Varga Z, Walter RB, Tiersch TR. Workshop Report: Cryopreservation of Aquatic Biomedical Models. *Cryobiology* 2019;86:120-129. [Link](#).

Lewis JK, Bischof J, Baslavsky I, Brockbank KGM, Fahy GM, Fuller BJ, Rabin Y, Tocchio A, Woods EJ, Wowk BG, Acker JP, Giwa S. The Grand Challenges of Organ Banking: Proceedings from the First Global Summit on Complex Tissue Cryopreservation. *Cryobiology* 2016;72(2):169-182. [Link](#).



Meneghel J, Kilbride P, Morris GJ. Cryopreservation as a Key Element in the Successful Delivery of Cell-Based Therapies—A Review. *Frontiers in Medicine: Gene and Cell Therapy* 2020;7:592242. doi:[10.3389/fmed.2020.592242](https://doi.org/10.3389/fmed.2020.592242). [Link](#).

U.S. National Science Foundation (NSF). *Solving Organ Shortage Through Organ Banking and Bioengineering*. 2015. <https://static1.squarespace.com/static/57d7d2ad15d5db47a2e81a13/t/58bccdc046c3c4c07ac685ed/1488768452341/OrganBankingRoadmap.pdf>. [Link](#).

Wachtel SS, Tiersch TR. *Ethical Considerations for the Application of Cryopreservation to Aquatic Species*, in CRYOPRESERVATION IN AQUATIC SPECIES (Tiersch TR, Mazik PM eds., 2000). [Link](#).

Ward A, Klassen DK, Franz KM, Giwa S, Lewis JK. Social, Economic, and Policy Implications of Organ Preservation Advances. *Current Opinion in Organ Transplantation* 2018;23:336-346. [Link](#).

## II. Guidance for Responsible Innovation

### A. Responsible Innovation/Risk Innovation

Arizona State University. *Risk Innovation Lab*. <http://riskinnovation.asu.edu/about/>. [Link](#).

Fisher E. Reinventing Responsible Innovation. *Journal of Responsible Innovation* 2020;7(1):1-5. [Link](#).

Lubberink R, Blok V, Van Ophem J, Omta O. Lessons for Responsible Innovation in the Business Context: A Systematic Literature Review of Responsible, Social and Sustainable Innovation Practices. *Sustainability* 2017;9:721-752. [Link](#).

Maynard AD. Navigating the Fourth Industrial Revolution. *Nature Nanotechnology* 2015;10:1005-1006. [Link](#).

Maynard AD. Why We Need Risk Innovation. *Nature Nanotechnology* 2015;10:730-731. [Link](#).

Maynard AD. Navigating the Risk Landscape. *Nature Nanotechnology* 2016;11:211-212. [Link](#).

Maynard AD. Thinking Innovatively about the Risks of Tech Innovation. *The Conversation*. Jan. 12, 2016. <https://theconversation.com/thinking-innovatively-about-the-risks-of-tech-innovation-52934>. [Link](#).

Maynard AD. Innovating Responsibly in a Culture of Entrepreneurship. *Edge of Innovation*. Aug. 13, 2019. <https://medium.com/edge-of-innovation/innovating-responsibly-in-a-culture-of-entrepreneurship-55c3d32bdc6f>. [Link](#).

Maynard AD. Why Risk Innovation is Critical to the Futures We Aspire To. *Edge of Innovation*. Nov. 5, 2020. <https://medium.com/edge-of-innovation/why-risk-innovation-is-critical-to-the-futures-we-aspire-to-a4ec96ef7516>. [Link](#).

Owen R, Macnaghten P, Stilgoe J. Responsible Research and Innovation: From Science in Society to Science for Society, With Society. *Science and Public Policy* 2012;39:751-760. [Link](#).

Owen R, Bessant J, Heintz M eds. RESPONSIBLE INNOVATION: MANAGING THE RESPONSIBLE EMERGENCE OF SCIENCE AND INNOVATION IN SOCIETY (2013). [Link](#).



- Peckham J. What is Responsible Innovation, and Why Should Tech Giants Take It Seriously? *Techradar*. Aug. 27, 2018. <https://www.techradar.com/news/what-is-responsible-innovation-and-why-should-tech-giants-take-it-seriously>. [Link](#).
- Schuurbijs D. What Happens in the Lab: Applying Midstream Modulation to Enhance Critical Reflection in the Laboratory. *Science and Engineering Ethics* 2011;17:769-788. [Link](#).
- Stilgoe J, Owen R, Macnaghten P. Developing a Framework for Responsible Innovation. *Research Policy* 2013;42:1568-1580. [Link](#).
- \*Ten Holter C. Participatory Design: Lessons and Directions for Responsible Research and Innovation. *Journal of Responsible Innovation* 2022;1-16. [Link](#).
- \*Urueña, S. Responsibility through Anticipation? The ‘Future Talk’ and the Quest for Plausibility in the Governance of Emerging Technologies. *NanoEthics* 2021;15(3):271-302. [Link](#).
- Valdivia WD, Guston DH. Responsible Innovation: A Primer for Policy Makers. *Center for Technology Innovation at Brookings*. May 2015. [https://www.brookings.edu/wp-content/uploads/2016/06/Valdivia-Guston\\_Responsible-Innovation\\_v9.pdf](https://www.brookings.edu/wp-content/uploads/2016/06/Valdivia-Guston_Responsible-Innovation_v9.pdf). [Link](#).
- B. Anticipatory Governance/Governance of Emerging Technologies**
- Fisher E, Mahanja RL, Mitcham C. Midstream Modulation of Technology: Governance from Within. *Bulletin of Science, Technology & Society* 2006;26:485-496. [Link](#).
- Fuerth LS. Foresight and Anticipatory Governance. *Foresight*. 2009;11(4):14-32. [Link](#).
- Guston DH. Understanding “Anticipatory Governance.” *Social Studies of Science* 2014;44:218-242. [Link](#).
- Kuzma J, Paradise J, Ramachandran G, Kim JA, Kokotovich A, Wolf SM. An Integrated Approach to Oversight Assessment for Emerging Technologies. *Risk Analysis* 2008;28:1197-1220. [Link](#).
- Lehoux P, Miller FA, William-Jones B. Anticipatory Governance and Moral Imagination: Methodological Insights from a Scenario-Based Public Deliberation Study. *Technological Forecasting & Social Change* 2020;151:119800. doi: [10.1016/j.techfore.2019.119800](https://doi.org/10.1016/j.techfore.2019.119800). [Link](#).
- Marchant GE, Meyer A, Scanlon M. Integrating Social and Ethical Concerns into Regulatory Decision-Making for Emerging Technologies. *Minnesota Journal of Law, Science & Technology* 2010;11:345-363. [Link](#).
- Marchant GE, Wallach W eds. EMERGING TECHNOLOGIES: ETHICS, LAW AND GOVERNANCE. (2017). [Link](#).
- Marchant GE. Emerging Technologies and the Courts. *Court Review* 2019;55:146-153. [Link](#).
- Michelson ES. Assessing the Societal Implications of Emerging Technologies: Anticipatory Governance in Practice (2016). [Link](#).
- Sarewitz D. *Anticipatory Governance of Emerging Technologies*, in THE GROWING GAP BETWEEN EMERGING TECHNOLOGIES AND LEGAL-ETHICAL OVERSIGHT: THE PACING PROBLEM (Marchant GE, Allenby BR, Herkert JR eds., 2011). [Link](#).
- C. Ethical Innovation in Nanotechnology**
- Barben D, Fisher E, Selin C, Guston DH. *Anticipatory Governance of Nanotechnology: Foresight, Engagement, and Integration*, in THE HANDBOOK OF SCIENCE AND



- TECHNOLOGY STUDIES (Hackett EJ, Amsterdamska O, Lynch M, Wajcman J eds., 3rd ed., 2008). [Link](#).
- Fisher E. Ethnographic Invention: Probing the Capacity of Laboratory Decisions. *NanoEthics* 2007;1:155-165. [Link](#).
- \*Heltzel A, Schuijjer JW, Willems WL, Kupper F, Broerse JEW. 'There Is Nothing Nano-Specific Here': A Reconstruction of the Different Understandings of Responsiveness in Responsible Nanotechnology Innovation. *Journal of Responsible Innovation* 2022;1-23. [Link](#).
- Karinen R, Guston DH. *Toward Anticipatory Governance: The Experience with Nanotechnology*, in GOVERNING FUTURE TECHNOLOGIES: NANOTECHNOLOGY AND THE RISE OF AN ASSESSMENT REGIME (Kaiser M, Kurath M, Maasen S, Rehmann-Sutter C eds., 2010). [Link](#).
- \*Kokotovich AE, Kuzma J, Cummings CL, Grieger K Responsible Innovation Definitions, Practices, and Motivations from Nanotechnology Researchers in Food and Agriculture. *Nanoethics* 2021;15:229-243. [Link](#).
- Marchant GE, Atkinson B, Banko D, Bromley J, Cseke E, Feldstein E, Garcia D, Grant JM, Hubach C, Silva M, Swinford RL, Willman S. The Biggest Issues for the Smallest Stuff: Nanotechnology Regulation and Risk Management. *Jurimetrics* 2012;52:243-277. [Link](#).
- Paradise J, Wolf SM, Kuzma J, Kuzhabekova AP. Developing U.S. Oversight Strategies for Nanobiotechnology: Learning from Past Oversight Experiences. *Journal of Law, Medicine & Ethics* 2009;37:688-705. [Link](#).
- Ramachandran G, Wolf SM, Paradise J, Kuzma J, Hall R, Kokkoli E, Fatehi L. Recommendations for Oversight of Nanobiotechnology: Dynamic Oversight for Complex and Convergent Technology. *Journal of Nanoparticle Research* 2011;13:1345-1371. [Link](#).
- Robinson DKR. Co-Evolutionary Scenarios: An Application to Prospecting Futures of the Responsible Development of Nanotechnology. *Technological Forecasting and Social Change* 2009;76:1222-1239. [Link](#).
- Selin C. Negotiating Plausibility: Intervening in the Future of Nanotechnology. *Science and Engineering Ethics* 2011;17:723-737. [Link](#).
- van Wezel AP, van Lente H, van de Sandt JJM, Bouwmeester H, Vandeberg RLJ, Sips AJAM. Risk Analysis and Technology Assessment in Support of Technology Development: Putting Responsible Innovation in Practice in a Case Study for Nanotechnology. *Integrated Environmental Assessment and Management* 2017;14(1):9-16. [Link](#).
- Wolf SM, Jones C. Designing Oversight for Nanomedicine Research in Human Subjects: Systematic Analysis of Exceptional Oversight for Emerging Technologies. *Journal of Nanoparticle Research* 2011;12:1449-1465. [Link](#).
- Wolf SM, McCullough J, Kahn JP, Jones C, eds. Symposium: Nanodiagnostics and Nanotherapeutics: Building Research Ethics & Oversight. *Journal Law, Medicine & Ethics* 2012;40:712-864. [Link](#).



#### **D. Public Opinion on Emerging Technologies**

Bäckstrand K. Multi-Stakeholder Partnerships for Sustainable Development: Rethinking Legitimacy, Accountability, and Effectiveness. *European Environment* 2006;16:290-306.

[Link.](#)

Callon M, Lascoumes P, Barthe Y. Acting in an Uncertain World: An Essay on Technical Democracy (Burchell G, trans., 2009). [Link.](#)

Goodin RE, Dryzek JS. Deliberative Impacts: The Macro-Political Uptake of Mini-Publics. *Politics & Society* 2006;34:219-244. [Link.](#)

\*Metcalfe J, Gascoigne T, Medvecky F, Nepote AC. Participatory Science Communication for Transformation. *Journal of Science Communication* 2022;21(02)E. [Link.](#)

Wilsdon J, Willis R. See-Through Science: Why Public Engagement Needs to Move Upstream. *Demos*. 2004. doi: [10.13140/RG.2.1.3844.3681](https://doi.org/10.13140/RG.2.1.3844.3681).

[https://www.researchgate.net/publication/277816762\\_See-through\\_Science\\_Why\\_public\\_engagement\\_needs\\_to\\_move\\_upstream](https://www.researchgate.net/publication/277816762_See-through_Science_Why_public_engagement_needs_to_move_upstream).

[Link.](#)

### **III. Organ Transplantation**

#### **A. Ethics and Regulatory Sources**

Brown RS, Higgins R, Pruett TL. The Evolution and Direction of OPTN Oversight of Live Organ Donation and Transplantation in the United States. *American Journal of Transplantation* 2009;9:31-34. [Link.](#)

Health Resources & Services Administration (HRSA). *Organ Donation Legislation and Policy*. <https://www.organdonor.gov/about-us/legislation-policy> (last updated April 2021). [Link.](#)

Kelly E. FDA Regulation of 3-D Printed Organs and Associated Ethical Challenges. *University of Pennsylvania Law Review* 2018;166:515-545. [Link.](#)

National Organ Transplantation Act of 1984. 42 U.S.C. §274. [Link.](#)

Organ Procurement and Transplantation Network (OPTN). *Policies Effective as of Oct. 7, 2021*. [https://optn.transplant.hrsa.gov/media/eavh5bf3/optn\\_policies.pdf](https://optn.transplant.hrsa.gov/media/eavh5bf3/optn_policies.pdf) (last updated Oct. 7, 2021). [Link.](#)

World Health Organization (WHO). WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation, WHA63.22 (2010).

[https://www.who.int/transplantation/Guiding\\_PrinciplesTransplantation\\_WHA63.22en.pdf](https://www.who.int/transplantation/Guiding_PrinciplesTransplantation_WHA63.22en.pdf). [Link.](#)

#### **B. Applications -- ELSI issues**

##### **1. Commercialization, Exploitation, and Trafficking**

Capron AM, Delmonico FL. Preventing Trafficking in Organs for Transplantation: An Important Facet of the Fight Against Human Trafficking. *Journal of Human Trafficking* 2015;1:56-64.

[Link.](#)

\*Conzen K, Pomfret E. *Ethical Issues in Living Donor Liver Transplantation*, in TEXTBOOK OF LIVER TRANSPLANTATION (Burra P ed., 2022) 219-238. [Link.](#)



- Council of Europe Convention Against Trafficking in Human Organs, March 25, 2015, C.E.T.S. 216. <https://rm.coe.int/16806dca3a>. [Link](#).
- The Declaration of Istanbul on Organ Trafficking and Transplant Tourism (2018 ed.). *Transplantation* 2019;103:218-219. [Link](#).
- Goodwin MB. Empires of the Flesh: Organ and Tissue Taboos. *Alabama Law Review* 2009;60:1219-1248. [Link](#).
- Haberal M, Cantarovich M, Muller E, Fung JJ, Sarwal M, Tullius SG, Ascher N. Call for an End to Unethical Transplant Practices: A Concerted Effort by the Transplant Community. *Transplantation* 2019;103:647-647. [Link](#).
- Jafar TH. Organ Trafficking: Global Solutions for a Global Problem. *American Journal of Kidney Diseases* 2009;54:1145-1157. [Link](#).
- Manzano A, Monaghan M, Potrata B, Clayton M. The Invisible Issue of Organ Laundering. *Transplantation* 2014;98:600-603. [Link](#).
- Martin DE, Van Assche K, Domínguez-Gil B, Lopez-Fraga M, Budiani-Saberi D, Lavee J, Tibell A, Moazam F, Muller E, Danovitch G, Codreanu I, Naicker S, Al Rukhaimi M, McGuinness S, Bakr MA, Moniruzzaman M, Capron AM, Delmonico FL. Prevention of Transnational Transplant-Related Crimes—What More Can Be Done? *Transplantation* 2016;100:1776-1784. [Link](#).
- Martin DE, Van Assche K, Dominguez-Gil B, Lopez-Fraga M, Gallont RG, Muller E, Capron AM. Strengthening Global Efforts to Combat Organ Trafficking and Transplant Tourism: Implications of the 2018 Edition of the Declaration of Istanbul. *Transplantation Direct* 2019;5(3):1-13. [Link](#).
- Shepp S. Priceless Kidney: The Ineffectiveness of Organ Trafficking Legislation. *Syracuse Journal of International Law and Commerce* 2019;46:379-402. [Link](#).
- Shimazono Y. The State of the International Organ Trade: A Provisional Picture Based on Integration of Available Information. *Bulletin of the World Health Organization*. 2007;85:955-962. [Link](#).

## **2. Equitable Allocation of Organs**

- Boulware LE, Mohottige D. The Seen and the Unseen: Race and Social Inequities Affecting Kidney Care. *Clinical Journal of the American Society of Nephrology* 2021;16:815-817. [Link](#).
- Cohen G. Organs Without Borders: Allocating Transplant Organs, Foreigners, and the Importance of the Nation-State. *Law & Contemporary Problems* 2014;77:175-215. [Link](#).
- Higgins RSD, Fishman JA. Disparities in Solid Organ Transplantation for Ethnic Minorities: Facts and Solutions. *American Journal of Transplantation* 2006;6:2556-2562. [Link](#).
- Kim JJ, Basu M, Plantinga L, Pastan SO, Mohan S, Smith K, Melanson T, Escoffery C, Patzer RE. Awareness of Racial Disparities in Kidney Transplantation Among Health Care Providers in Dialysis Facilities. *Clinical Journal of the American Society of Nephrology* 2018;13:772-781. [Link](#).





- Kim I, Martins P. Achieving Racial Equity in Organ Transplantation. *United Network for Organ Sharing (UNOS)*. June 15, 2020. <https://unos.org/news/racial-equity-in-transplantation/>. [Link](#).
- Mathur AK, Sonnenday CJ, Merion RM. Race and Ethnicity in Access to and Outcomes of Liver Transplantation: A Critical Literature Review. *American Journal of Transplantation*. 2009;9:2662-2668. [Link](#).
- Morla-Gonzalez M, Moya-Guillem C, Rodriguez-Arias D, de Miguel Beriain I, Molina-Perez A, Ortega-Deballon I. Addressing Organ Shortage: An Automatic Organ Procurement Model as a Proposal. *Clinical Ethics* 2021;16:278-290. [Link](#).
- National Academies of Sciences, Engineering, and Medicine (NASEM). *Realizing the Promise of Equity in the Organ Transplantation System*. 2022. <https://www.nap.edu/catalog/26364/realizing-the-promise-of-equity-in-the-organ-transplantation-system>. [Link](#).
- Nephew LD, Serper M. Racial, Gender, and Socioeconomic Disparities in Liver Transplantation. *Liver Transplantation* 2021;27:900-912. [Link](#).
- Organ Procurement and Transplantation Network (OPTN). *How Organ Allocation Works*. <https://optn.transplant.hrsa.gov/learn/about-transplantation/how-organ-allocation-works/> (last accessed Nov. 2, 2021). [Link](#).
- \*Park C, Jones MM, Kaplan S, Koller FL, Wilder JM, Boulware LE, McElroy LM. A Scoping Review of Inequities in Access to Organ Transplant in the United States. *International Journal for Equity in Health* 2022;21:22. [Link](#).
- Smith JM. The Gross Inequality of Organ Transplants in America. *The New Republic*. Nov. 8, 2017. <https://newrepublic.com/article/145682/gross-inequality-organ-transplants-america>. [Link](#).
- Tumin D, Horan J, Shrider EA, Smith SA, Tobias JD, Hayes D, Foraker RE. County Socioeconomic Characteristics and Heart Transplant Outcomes in the United States. *American Heart Journal* 2017;190:104-112. [Link](#).
- \*van de Klundert J, van der Hagen L, Markus A. Eliminating Transplant Waiting Time Inequities – With an Application to Kidney Allocation in the USA. *European Journal of Operational Research* 2022;297(3):977-985. [Link](#).

### 3. Human Testing of Manipulated Organs

- Cohen IG. Organ Donor Intervention Trials and Risk to Bystanders: An Ethical Analysis. *Clinical Trials* 2019;16:463-465. [Link](#).
- National Academies of Sciences, Engineering, and Medicine (NASEM). *Opportunities for Organ Donation Intervention Research, Saving Lives by Improving the Quality and Quantity of Organs for Transplantation*. 2017. <https://www.nap.edu/catalog/24884/opportunities-for-organ-donor-intervention-research-saving-lives-by-improving>. [Link](#).
- U.S. Department of Health and Human Services (HHS). *Issues Surrounding Deceased Donor Intervention Research Under 45 CFR Part 46*. <https://www.hhs.gov/ohrp/sachrp->



[committee/recommendations/august-12-2020-attachment-b-deceased-donor-intervention/index.html](#) (last updated Sept. 17, 2020). [Link](#).

U.S. Food and Drug Administration (FDA). *Inside Clinical Trials: Testing Medical Products in People*. <https://www.fda.gov/drugs/information-consumers-and-patients-drugs/inside-clinical-trials-testing-medical-products-people> (last updated Nov. 16, 2014). [Link](#).

U.S. Food and Drug Administration (FDA). *Institutional Review Boards (IRBs) and Protection of Human Subjects in Clinical Trials*. <https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/institutional-review-boards-irbs-and-protection-human-subjects-clinical-trials> (last updated Sept. 11, 2019). [Link](#).

Zhang S. The Ethics Issue Blocking Organ Transplant Research. *The Atlantic*. Aug. 15, 2017. <https://www.theatlantic.com/health/archive/2017/08/organ-donation-consent/536277/>. [Link](#).

#### IV. Cells, Tissues, and Other Medical Products of Human Origin

##### A. Ethics and Regulatory Sources

American Association of Tissue Banks (AATB). *AATB Guidance Documents*.

<https://www.aatb.org/guidance-documents> (last accessed Nov. 2, 2021). [Link](#).

Annaratone L, De Palma G, Bonizzi G, Sapino A, Botti G, Berrino E, Mannelli C, Arcella P, Di Martino S, Steffan A, Daidone MG, Canzonieri V, Parodi B, Paradiso AV, Barberis M, Marchio C. Basic Principles of Biobanking: From Biological Samples to Precision Medicine for Patients. *Virchows Archiv* 2021;479:233-246. [Link](#).

Ellul B, Galea G. *Ethical and Regulatory Aspects of Cell and Tissue Banking*, in *ESSENTIALS OF TISSUE AND CELLS BANKING* (Galea G, Turner M, Zahra S eds., 2021). [Link](#).

Lee MH, Whittlesey KJ, Dang JM, Colehour M, Arcidiacono J, Lazarus E, Kaplan DS, Dufor CN, Batra A, Hilbert SL, Grayeski DL, McFarland R, Witten C. *Overview of the FDA Regulatory Process*, in *ESSENTIALS OF STEM CELL BIOLOGY* (Lanza R, Atala A eds., 2nd ed. 2014). [Link](#).

Martin DE. Ethical Aspects of Medical Products of Human Origin. *ISBT Science Series* 2017;12:281-287. [Link](#).

Mendicino M, Yong F, Griffin D, Gunter KC, Nichols K. Current State of U.S. Food and Drug Administration Regulation for Cellular and Gene Therapy Products: Potential Cures on the Horizon. *Cytotherapy* 2019;21:699-724. [Link](#).

Schulz-Baldes A, Biller-Adorno N, Capron AM. International Perspectives on the Ethics and Regulation of Human Cell and Tissue Transplantation. *Bulletin of the World Health Organization* 2007;85:941-948. [Link](#).

Thompson BM, Kendall LR. Regulating the Human Tissue Trade. *Health Care Law Monthly* 2009;1:2-8. [Link](#).

U.S. Environmental Protection Agency (EPA), U.S. Food and Drug Administration (FDA), U.S. Department of Agriculture (USDA). *Modernizing the Regulatory System for Biotechnology Products: Final Version of the 2017 Update to the Coordinated Framework*



- for the Regulation of Biotechnology*. 2017. [https://www.epa.gov/sites/default/files/2017-01/documents/2017\\_coordinated\\_framework\\_update.pdf](https://www.epa.gov/sites/default/files/2017-01/documents/2017_coordinated_framework_update.pdf). [Link](#).
- U.S. Department of Health & Human Services (HHS). About Blood and Tissue Safety and Availability. <https://www.hhs.gov/oidp/topics/blood-tissue-safety/about/index.html> (last updated Oct. 7, 2019). [Link](#).
- U.S. Food and Drug Administration (FDA). *Testing Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/P): Specific Requirements*. <https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/testing-donors-human-cells-tissues-and-cellular-and-tissue-based-products-hctp-specific-requirements> (last updated May 3, 2019). [Link](#).
- U.S. Food and Drug Administration (FDA). *Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use; Guidance for Industry and Food and Drug Administration Staff*. July 21, 2020. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal>. [Link](#).
- U.S. Food and Drug Administration (FDA). *Tissue & Tissue Products*. <https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products> (last updated Jan. 27, 2021). [Link](#).
- U.S. Food and Drug Administration (FDA). *CBER Regulated Products*. <https://www.fda.gov/industry/regulated-products/cber-regulated-products> (last updated Feb. 3, 2021). [Link](#).
- U.S. Food and Drug Administration (FDA). *Regenerative Medicine Advanced Therapy Designation*. <https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation> (last updated Oct. 6, 2021). [Link](#).
- Yano K, Speidel AT, Yamato M. Four Food and Drug Administration Draft Guidance Documents and the REGROW Act: A Litmus Test for Future Changes in Human Cell- and Tissue-Based Products Regulatory Policy in the United States? *Journal of Tissue Engineering and Regenerative Medicine* 2018;12:1579-1593. [Link](#).

## **B. Applications -- ELSI Issues**

### **1. Biobanking**

- Allen SC, Lohani M, Hendershot KA, Deal TR, White T, Dixon MD, Pentz RD. Patient Perspectives on Compensation for Biospecimen Donation. *AJOB Empirical Bioethics* 2018;9:77-81. [Link](#).
- Andrews LB. Harnessing the Benefits of Biobanks. *Journal of Law, Medicine & Ethics* 2005;33:22-30. [Link](#).
- Ashcroft JW, Macpherson CC. The Complex Ethical Landscape of Biobanking. *The Lancet Public Health* 2019;4:e274-e275. [Link](#).



- Biller-Andorno N, Capron AM, Elger B eds. ETHICAL ISSUES GOVERNING BIOBANKS: GLOBAL PERSPECTIVES (2016). [Link](#).
- Caulfield T, Burningham S, Joly Y, Master Z, Shabani M, Borry P, Becker A, Burgess M, Calder K, Critchley C, Edwards K, Fullerton SM, Gottwies H, Hyde-Lay R, Illes J, Isasi R, Kato K, Kaye J, Knoppers B, Lynch J, McGuire A, Meslin E, Nicol D, O’Doherty K, Obuhu U, Otlowski M, Pullman D, Ries N, Scott C, Sears M, Wallace H, Zawati MH. A Review of the Key Issues Associated with the Commercialization of Biobanks. *Journal of Law and the Biosciences* 2014;1(1):94-110. [Link](#).
- Chalmers D, Burgess M, Edwards K, Kaye J, Meslin EM, Nicol D. Marking Shifts in Human Research Ethics in the Development of Biobanking. *Public Health Ethics* 2015;8:63-71. [Link](#).
- Hainut P, Vaught J, Zatloukal K, Pasterk M eds. BIOBANKING OF HUMAN SPECIES: LESSONS FROM 25 YEARS OF BIOBANKING EXPERIENCE (2021). [Link](#).
- Kinkorová J. Education for Future Biobankers: The State-of-the-Art and Outlook. *EPMA Journal* 2021;12(1):15-25. [Link](#).
- Phillips GO. The Emergence and Pitfalls of International Tissue Banking. *Cell Tissue Banking* 2018;19:167-173. [Link](#).
- Rychnovska D. Anticipatory Governance in Biobanking: Security and Risk Management in Digital Health. *Science and Engineering Ethics* 2021;27(30):1-18. [Link](#).
- Sudoj A, De Vries J, Kamuya D. A Scoping Review of Considerations and Practices for Benefit Sharing in Biobanking. *BMC Medical Ethics* 2021;22(102):1-16. [Link](#).
- Yaghoobi H, Hosseini SA. History of the Largest Global Biobanks, Ethical Challenges, Registration, and Biological Samples Ownership. *Journal of Public Health* 2021. doi:[0.1007/s10389-021-01504-2](https://doi.org/10.1007/s10389-021-01504-2). [Link](#).
- 2. Production and Scaling Up of Cell Therapies**
- Chalasanani R, Hershey TB, Gellad WF. Cost and access implications of defining CAR-T therapy as a drug. *JAMA Health Forum* 2020;1(7):e200868. doi:[10.1001/jamahealthforum.2020.0868](https://doi.org/10.1001/jamahealthforum.2020.0868). [Link](#).
- Criswell T, Swart C, Stoudemire J, Brockbank K, Floren M, Eaker S, Hunsberger J. Shipping and Logistics Considerations for Regenerative Medicine Therapies. *Stem Cells Transl Med* 2022. doi: [10.1093/stcltm/szab025](https://doi.org/10.1093/stcltm/szab025).
- Dai X, Mei Y, Cai D, Han W. Standardizing CAR-T Therapy: Getting it Scaled Up. *Biotechnology Advances* 2019;37(1):239-245. [Link](#).
- Food and Drug Law Institute (FDLI). *Regulations of CAR T-Cell Therapies—The Past, Present, and Future*. 2020. <https://www.fdpi.org/2020/12/regulations-of-car-t-cell-therapies-the-past-present-and-future-is-it-safe/>. [Link](#).
- Papathanasiou MM, Stamatias C, Lakelin M, Farid S, Tichener-Hooker N, Shah N. Autologous CAR T-Cell Therapies Supply Chain: Challenges and Opportunities? *Cancer Gene Therapy* 2020;27:799-809. [Link](#).



## V. Microphysiological Systems and Organoids

### A. Ethics and Regulatory Sources

American Association of Blood Banks (AABB). *How are Stem Cells Regulated: United States*. <https://www.aabb.org/news-resources/resources/cellular-therapies/facts-about-cellular-therapies/how-are-stem-cells-regulated> (last accessed Nov. 2, 2021). [Link](#).

\*Barnhart AJ, Dierickx K. The Many Moral Matters of Organoid Models: A Systematic Review of Reasons. *Medicine, Health Care and Philosophy* 2022. Epub ahead of print. [Link](#).

Bredenoord AL, Clevers H, Knoblich JA. Human Tissues in a Dish: The Research and Ethical Implications of Organoid Technology. *Science* 2017;355(6322):1-7. [Link](#).

Hargrove-Grimes P, Low LA, Tagle DA. Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development. *Cells Tissues Organs* 2021. doi:[10.1159/000517422](https://doi.org/10.1159/000517422). [Link](#).

Hyun I. The Bioethics of Stem Cell Research and Therapy. *Journal of Clinical Investigation* 2010;120(1):71-75. [Link](#).

International Society for Stem Cell Research (ISSCR). *ISSCR Guidelines for Stem Cell Research and Clinical Translation (2021 Update)*. <https://www.isscr.org/policy/guidelines-for-stem-cell-research-and-clinical-translation>. [Link](#).

Mollaki V. Ethical Challenges in Organoid Use. *BioTech* 2021;10(12):1-19. [Link](#).

Munsie M, Hyun I, Sugarman J. Ethical Issues in Human Organoid and Gastruloid Research. *Development* 2017;144:942-945. [Link](#).

National Academies of Sciences, Engineering, and Medicine (NASEM). *Guidelines for Human Embryonic Stem Cell Research*. 2005. <https://www.nap.edu/catalog/11278/guidelines-for-human-embryonic-stem-cell-research>. [Link](#).

National Academies of Sciences, Engineering, and Medicine (NASEM). *2008 Amendments to the National Academies' Guidelines for Human Embryonic Stem Cell Research*. 2008. <https://www.nap.edu/catalog/12260/2008-amendments-to-the-national-academies-guidelines-for-human-embryonic-stem-cell-research>. [Link](#).

Sawai T, Hayashi Y, Niikawa T, Shepherd J, Thomas E, Lee TL, Erler A, Watanabe M, Sakaguchi H. Mapping the Ethical Issues of Brain Organoid Research and Application. *AJOB Neuroscience* 2021. doi:[10.1080/21507740.2021.1896603](https://doi.org/10.1080/21507740.2021.1896603). [Link](#).

U.S. National Institutes of Health (NIH). *NIH Guidelines for Human Stem Cell Research*. 2009. <https://stemcells.nih.gov/research-policy/guidelines-for-human-stem-cell-research>. [Link](#).

U.S. National Institutes of Health (NIH). *Update on Changes to NIH Requirements Regarding Proposed Human Fetal Tissue Research*. Apr. 16, 2021. <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-111.html>. [Link](#).



## B. Applications -- ELSI Issues

Boers SN, Delden JJM van, Bredenoord AL. Organoids as Hybrids: Ethical Implications for the Exchange of Human Tissues. *Journal of Medical Ethics* 2019;45:131-139. [Link](#).

\*Evans JH. The Public's Ethical Issues with Brain Organoid Research and Application. *AJOB Neuroscience* 2022;13(2):101-103. [Link](#).

Ewart L, Dehne EM, Fabre K, Gibbs S, Hickman J, Hornberg E, Ingelman-Sundberg M, Jang KJ, Jones DR, Lauschke VM, Marx U, Mettetal JT, Pointon A, Williams D, Zimmermann WH, Newham P. Application of Microphysiological Systems to Enhance Safety Assessment in Drug Discovery. *Annual Review of Pharmacology and Toxicology* 2018;52:65-82. [Link](#).

Lensink MA, Boers SN, Jongsma KR, Carter SE, van der Ent C, Bredenoord AL. Organoids for Personalized Treatment of Cystic Fibrosis: Professional Perspectives on the Ethics and Governance of Organoid Biobanking. *Journal of Cystic Fibrosis* 2021;20:443-451. [Link](#).

Marx U, Akabane T, Andersson TB, Baker E, Beilmann M, Beken S, Bendler-Schwaab S, Cirit M, David R, Dehne EM, Durieux I, Ewart L, Fitzpatrick SC, Frey O, Fuchs F, Griffith LG, Hamilton GA, Hartung T, Hoeng J, Hogberg H, Hughes DJ, Ingber DE, Iskandar A, Kanamori T, Kojima H, Kuehl J, Leist M, Li B, Loskill P, Mendrick DL, Neumann T, Pallocca G, Rusyn I, Smirnova L, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tsyb S, Trapecar M, van de Water B, van den Eijnden-van Raaij J, Vulto P, Watanabe K, Wolf A, Zhou X, Roth A. Biology-Inspired Microphysiological Systems to Advance Patient Benefit and Animal Welfare in Drug Development. *ALTEX* 2020;37(3):365-394. [Link](#).

Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development. *Cell Stem Cell* 2018;22:310-324. [Link](#).

\*Stoeklé H, Ivasilevitch A, Marignac G, Hervé C. Ethical Issues of Brain Organoids: Well Beyond "Consciousness"? *AJOB Neuroscience* 2022;13(2):109-111. [Link](#).

\*Walker MJ, Nielsen J, Goddard E, Harris A, Hutchison K. Induced Pluripotent Stem Cell-Based Systems for Personalising Epilepsy Treatment: Research Ethics Challenges and New Insights for the Ethics of Personalised Medicine. *AJOB Neuroscience* 2022;13(2): 120-31. [Link](#).

## VI. Whole Organisms

### A. Model Organisms

#### 1. Ethics and Regulatory Sources

Cartner SC, Durboraw E, Watts A. *Regulations, Policies and Guidelines Pertaining to the Use of Zebrafish in Biomedical Research*, in THE ZEBRAFISH IN BIOMEDICAL RESEARCH (Cartner SC, Eisen JS, Farmer SC, Guillemin KJ, Kent ML, Sanders GE eds., 2020). [Link](#).

de Abreu MS, et al. Legal Aspects of Zebrafish Neuropharmacology and Neurotoxicology Research. *Regulatory Toxicology and Pharmacology* 2019;101:65-70. [Link](#).



- Goodwin N, Karp NA, Blackledge S, Clark B, Keeble R, Kovacs C, Murray KN, Price M, Thompson P, Bussell J. Standardized Welfare Terms for the Zebrafish Community. *Zebrafish* 2016;13(Suppl 1):S164-S168. [Link](#).
- Kelly JR, Benson SA. Inconsistent Ethical Regulation of Larval Zebrafish in Research. *Journal of Fish Biology* 2020;97(2):324-327. [Link](#).
- Lawrence C, Sanders GE, Varga ZM, Baumann DP, Freeman A, Baur B, Francis M. Regulatory Compliance and the Zebrafish. *Zebrafish* 2009;6:453-456. [Link](#).
- Sanders GE. Zebrafish Housing, Husbandry, Health, and Care: IACUC Considerations. *ILAR Journal* 2012;53:205-207. [Link](#).

## 2. Applications --ELSI Issues

- Torres L, Hu E, Tiersch TR. Cryopreservation in Fish: Current Status and Pathways to Quality Assurance and Quality Control in Reproductive Development. *Reproduction, Fertility and Development*. 2016;28(8):1105-1111. [Link](#).
- Torres L, Tiersch TR. Addressing Reproducibility in Cryopreservation, and Considerations Necessary for Commercialization and Community Development in Support of Genetic Resources of Aquatic Species. *Journal of the World Aquaculture Society* 2018;49:644-663. [Link](#).

## B. Pathogens

### 1. Ethics and Regulatory Sources

- U.S. Centers for Disease Control and Prevention (CDC). *CDC Bioterrorism Agents/Diseases (by category)*. <https://emergency.cdc.gov/agent/agentlist-category.asp> (last updated Apr. 4, 2018). [Link](#).
- U.S. Centers for Disease Control and Prevention (CDC); U.S. Department of Agriculture (USDA). *Federal Select Agent Program*. <https://www.selectagents.gov/sat/index.htm> (last updated Sept. 10, 2020). [Link](#).
- U.S. Department of Health and Human Services (HHS). Public Health Emergency (PHE): Biosecurity FAQ. <https://www.phe.gov/s3/BioriskManagement/biosecurity/Pages/Biosecurity-FAQ.aspx> (last updated Apr. 26, 2017). [Link](#).
- U.S. National Institutes of Health (NIH). *National Science Advisory Board for Biosecurity (NSABB)*. <https://osp.od.nih.gov/biotechnology/national-science-advisory-board-for-biosecurity-nsabb/#about> (last accessed Nov. 2, 2021). [Link](#).
- World Health Organization (WHO). *Biorisk Management: Laboratory Biosecurity Guidance*. Sept. 2006. [https://www.who.int/csr/resources/publications/biosafety/WHO\\_CDS\\_EPR\\_2006\\_6.pdf](https://www.who.int/csr/resources/publications/biosafety/WHO_CDS_EPR_2006_6.pdf). [Link](#).



## 2. Applications--ELSI Issues

Jaskiewicz JJ, Sandlin RD, Swei AA, Widmer G, Toner M, Tzipori S. Cryopreservation of Infectious *Cryptosporidium Parvum* Oocysts. *Nature Communications* 2018;9:2883. doi: [10.1038/s41467-018-05240-2](https://doi.org/10.1038/s41467-018-05240-2). [Link](#).

Jaskiewicz JJ, Sevenler D, Swei AA, Widmer G, Toner M, Tzipori S, Sandlin RD. Cryopreservation of Infectious *Cryptosporidium Parvum* Oocysts Achieved Through Vitrification Using High Aspect Ratio Specimen Containers. *Scientific Reports* 2020;10(1):11711. doi: [10.1038/s41598-020-68643-6](https://doi.org/10.1038/s41598-020-68643-6). [Link](#).

Roux J, Zeghidi M, Villar S, Kozlakidis Z. Biosafety and Biobanking: Current Understanding and Knowledge Gaps. *Biosafety and Health* 2021;3:244-348. [Link](#).

## VII. Environmental Uses

### A. Ethics and Regulatory Sources

Bagley MA, Rai AK. The Nagoya Protocol and Synthetic Biology Research: A Look at the Potential Impacts. *Synthetic Biology Project*. 2013. [https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=5916&context=faculty\\_scholarship](https://scholarship.law.duke.edu/cgi/viewcontent.cgi?article=5916&context=faculty_scholarship). [Link](#).

Barnhill-Dilling SK, Delborne JA. Whose Intentions? What Consequences? Interrogating “Intended Consequences” for Conservation with Environmental Biotechnology. *Conservation Science and Practice* 2021;3(4):e406. doi: [10.1111/csp2.406](https://doi.org/10.1111/csp2.406). [Link](#).

Campbell LD ed. International Society for Biological and Environmental Repositories (ISBER). BEST PRACTICES: RECOMMENDATIONS FOR REPOSITORIES (4th ed. 2018). [Link](#).

Collins JE, Rabone M, Vanagt T, Amon DJ, Gobin J, Huys I. Strengthening the Global Network for Sharing of Marine Biological Collections: Recommendations for a New Agreement for Biodiversity Beyond National Jurisdiction. *ICES Journal of Marine Science* 2020;78:305-314. [Link](#).

Comizzoli P, Holt WV. Implications of the Nagoya Protocol for Genome Resource Banks composed of Biomaterials from Rare and Endangered Species. *Reproduction, Fertility, and Development* 2016;28:1145-1151. [Link](#).

Commission on Genetic Resources for Food and Agriculture, The International Treaty on Plant Genetic Resources for Food and Agriculture, at <https://www.fao.org/plant-treaty/overview/texts-treaty/en/>. 2009. [Link](#).

Congressional Research Service. RL33152. The National Environmental Policy Act (NEPA): Background and Implementation. 2011. [Link](#).

Convention on Biological Diversity, June 5, 1992, 1760 U.N.T.S. 79, 143; 31 I.L.M. 818 (1992). [Link](#).

Esquinas-Alcázar J. Protecting Crop Genetic Diversity for Food Security: Political, Ethical and Technical Challenges. *Nature Reviews Genetics* 2005;6:946-953. [Link](#).





- Food and Agriculture Organization of the United Nations (FAO). *Cryoconservation of Animal Genetic Resources*. 2012. <https://www.fao.org/3/i3017e/i3017e00.htm>. [Link](#).
- International Plant Protection Convention, Dec. 6, 1951, 150 U.N.T.S. 67 (revised Nov. 28, 1979). <https://www.ippc.int/en/core-activities/governance/convention-text/>. [Link](#).
- Kohl PA, Brossard D, Scheufele DA, Xenos MA. Public Views About Editing Genes in Wildlife for Conservation. *Conservation Biology* 2019;33:1286-1295. [Link](#).
- Lajaunia C. From a Variety of Ethics to the Integrity and Congruence of Research on Biodiversity Conservation. *Asian Bioethics Review* 2018;10:313-332. [Link](#).
- Lallier LE, McMeel O, Greiber T, Vanagt T, Dobson ADW, Jaspars M. Access to and Use of Marine Genetic Resources: Understanding the Legal Framework. *Natural Product Reports* 2014;31:612-614. [Link](#).
- Lubell M, Morrison TH. Institutional Navigation for Polycentric Sustainability Governance. *Nature Sustainability* 2021;4:664-671. [Link](#).
- Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their Utilization to the Convention on Biological Diversity, Oct. 29, 2010, UNEP/CBD/COP/DEC/X/1. [Link](#).
- Phelan R, Baumgartner B, Brand S, Brister E, Burgiel SW, Charo RA, Coche I, Cofrancesco A, Delborne JA, Edwards O, Fisher JP, Gaywood M, Gordon DR, Howald G, Hunter ME, Kareiva P, Mankad A, Marvier M, Moseby K, Newhouse AE, Novak BJ, Ohrstrom G, Olson S, Palmer MJ, Palumbi S, Patterson N, Pedrono M, Pelegri F, Rohwer Y, Ryder OA, Saah JR, Scheller Rm, Seddon PJ, Shaffer HB, Shapiro B, Sweeney M, Tercek MR, Thizy D, Tilt W, Weber M, Wegrzyn RD, Whitelaw B, Winkler M, Wodak J, Zimring M, Robbins P. Intended Consequences Statement. *Conservation Science and Practice* 2021;3(4):e371. doi: [10.1111/csp2.371](https://doi.org/10.1111/csp2.371). [Link](#).
- U.S. Environmental Protection Agency (EPA). *National Environmental Policy Act Review Process*. <https://www.epa.gov/nepa/national-environmental-policy-act-review-process> (last updated Oct. 25, 2021). [Link](#).
- U.S. Fish & Wildlife Service (FWS). *Endangered Species Act: Overview*. <https://www.fws.gov/endangered/laws-policies/> (last updated Jan. 30, 2020). [Link](#).
- U.S. Fish & Wildlife Service (FWS). *U.S. Conservation Laws*. <https://www.fws.gov/international/laws-treaties-agreements/us-conservation-laws/> (last accessed Nov. 2, 2021). [Link](#).
- van Eeden LM, Slagle K, Newsome TM, Crowther MS, Dickman CR, Bruskotter JT. Exploring Nationality and Social Identity to Explain Attitudes Toward Conservation Actions in the United States and Australia. *Conservation Biology* 2020;34:1165-1175. [Link](#).
- Vucetich JA, Macdonald EA, Burnham D, Bruskotter JT, Johnson DDP, Macdonald DW. Finding Purpose in the Conservation of Biodiversity by the Commingling of Science and Ethics. *Animals* 2021;11(3):837. doi: [10.3390/ani11030837](https://doi.org/10.3390/ani11030837). [Link](#).



Watanabe ME. The Nagoya Protocol on Access and Benefit Sharing: International Treaty Poses Challenges for Biological Collections. *BioScience* 2015;65:543-550. [Link](#).

## **B. Applications -- ELSI Issues**

### **1. Biorepositories to Protect Biodiversity**

- Groeneveld LF, Gregusson S, Guldbrandsten B, Hiemstra SJ, Hveem K, Kantanen J, Lohi H, Stroemstedt L, Berg P. Domesticated Animal Biobanking: Land of Opportunity. *PLoS Biology* 2016;14(7):e1002523. doi:[10.3390/ani11030837](https://doi.org/10.3390/ani11030837). [Link](#).
- Hagedorn M, van Oppen MJH, Carter V, Henley M, Abrego D, Puill-Stephan E, Negri A, Heyward A, MacFarlane D, Spindler R. First Frozen Repository for the Great Barrier Reef Coral Created. *Cryobiology* 2012;65:157-158. [Link](#).
- Hagedorn M, Carter VL, Henley EM, van Oppen MJH, Hobbs R, Spindler RE. Producing Coral Offspring with Cryopreserved Sperm: A Tool for Coral Reef Restoration. *Scientific Reports* 2017;7(1):14432. doi:[10.1038/s41598-017-14644-x](https://doi.org/10.1038/s41598-017-14644-x). [Link](#).
- Mooney A. The Value of Ex Situ Collections for Global Biodiversity Conservation in the Wild (PhD thesis, Trinity College Dublin). 2021. [http://www.tara.tcd.ie/bitstream/handle/2262/95533/Andrew\\_Mooney\\_Thesis\\_Revised\\_TARA.pdf?sequence=6](http://www.tara.tcd.ie/bitstream/handle/2262/95533/Andrew_Mooney_Thesis_Revised_TARA.pdf?sequence=6). [Link](#).
- Pathak MR, Abido M. The Role of Biotechnology in the Conservation of Biodiversity. *Journal of Experimental Biology and Agricultural Sciences* 2014;2:352-363. [Link](#).
- Purdy PH, Wilson CS, Spiller SF, Blackburn HD. Biobanking Genetic Resources: Challenges and Implementation at the USDA National Animal Germplasm Program. *Reproduction, Fertility, and Development* 2016;28:1072-1078. [Link](#).
- San Diego Zoo Wildlife Alliance. Frozen Zoo®. <https://science.sandiegozoo.org/resources/frozen-zoo%C2%AE> (last accessed Nov. 2, 2021). [Link](#).
- Smithsonian Global. Reef Recovery Initiative. <https://global.si.edu/projects/reef-recovery-initiative> (last accessed Nov. 2, 2021). [Link](#).
- Smithsonian National Museum of Natural History. Global Genome Initiative. <https://naturalhistory.si.edu/research/global-genome-initiative> (last accessed Nov. 2, 2021). [Link](#).
- U.S. Department of Agriculture (USDA) Agricultural Research Service. *National Animal Germplasm Program (NAGP)* <https://www.ars.usda.gov/plains-area/fort-collins-co/center-for-agricultural-resources-research/paagrpru/docs/animal/national-animal-germplasm-program-nagp/> (last updated Apr. 19, 2019). [Link](#).
- U.S. National Institute of Standards and Technology (NIST). *NIST Biorepository*. <https://www.nist.gov/programs-projects/nist-biorepository> (last updated April 8, 2021). [Link](#).



## 2. Combining Advanced Biopreservation with Other Technologies (Like De-Extinction or Gene Drive Technology)

Carlin NF, Wurman I, Zakim T. How to Permit Your Mammoth: Some Legal Implications of “De-Extinction.” *Stanford Environmental Law Journal* 2014;33(1):3-57. [Link](#).

Revive & Restore. The Genetic Rescue Toolkit. <https://reviverestore.org/what-we-do/genetic-rescue-toolkit/> (last accessed Nov. 2, 2021). [Link](#).

Sandler RL, Moses L, Wisely SM. An Ethical Analysis of Cloning for Genetic Rescue: Case Study of the Black-Footed Ferret. *Biological Conservation* 2021;257:109118. doi:[10.1016/j.biocon.2021.109118](https://doi.org/10.1016/j.biocon.2021.109118). [Link](#).

Valdez RX, Kuzma J, Cummings CL, Peterson MN. Anticipating Risks, Governance Needs, and Public Perceptions of De-Extinction. *Journal of Responsible Innovation* 2019;6:211-231. [Link](#).

Wagner N, Hochkirch A, Martin H, Matenaar D, Rohde K, Wacht F, Wesch C, Wirtz S, Klein R, Lotters S, Proelss A, Veith M. De-Extinction, Nomenclature, and the Law. *Science* 2017;356:1016-1017. [Link](#).

Wayne RK, Shaffer HB. Hybridization and Endangered Species Protection in the Molecular Era. *Molecular Ecology* 2016;25:2680-2689. [Link](#).

## VIII. Aquaculture & Food Production

### A. Ethics and Regulatory Sources

Abate TG, Nielsen R, Nielsen M. Agency Rivalry in a Shared Regulatory Space and its Impact on Social Welfare: The Case of Aquaculture Regulation. *Aquaculture Economics & Management* 2018;22:27-48. [Link](#).

Davies IP, Carranza V, Froehlich HE, Gentry RR, Kareiva P, Halpern B. Governance of Marine Aquaculture: Pitfalls, Potential, and Pathways Forward. *Marine Policy* 2019;104:29-36. [Link](#).

DeWeerd S. Can Aquaculture Overcome its Sustainability Challenges? *Nature* 2020;588: S60-S62. [Link](#).

Fairbanks L. Policy Mobilities and the Sociomateriality of U.S. Offshore Aquaculture Governance. *EPC: Politics and Space* 2019;37:849-867. [Link](#).

Food and Agriculture Organization of the United Nations (FAO). The State of World Fisheries and Aquaculture 2020. doi:[10.4060/ca9229en](https://doi.org/10.4060/ca9229en). <https://www.fao.org/documents/card/en/c/ca9229en>. [Link](#).

Grigorakis K. Ethical Issues in Aquaculture Production. *Journal of Agricultural and Environmental Ethics* 2010;23:345-370. [Link](#).

Harrell RM. Bioethical Considerations of Advancing the Application of Marine Biotechnology and Aquaculture. *Marine Drugs* 2017;15(7):197. doi:[10.3390/md15070197](https://doi.org/10.3390/md15070197). [Link](#).



- Lowenstein E. Regulating the Blue Revolution: A Sea of Change for the United States' Offshore Aquaculture Industry or a Missed Opportunity for Increased Sustainability. *University of Miami International and Comparative Law Review* 2019; 26;473-498. [Link](#).
- National Agricultural Law Center. *Aquaculture: Overview*. <https://nationalaglawcenter.org/research-by-topic/aquaculture/> (last accessed Nov. 2, 2021). [Link](#).
- Upton HF. Congressional Research Service. R45952. U.S. Offshore Aquaculture Regulation and Development (2019). [Link](#).
- U.S. Department of Agriculture (USDA). *Subcommittee on Aquaculture (SCA) Federal Agency Aquaculture Profile Series: Regulatory Agencies*. <https://www.ars.usda.gov/SCA/factsheet.html> (last accessed Nov. 2, 2021). [Link](#).
- U.S. Food and Drug Administration (FDA). *Seafood Guidance Documents & Regulatory Information*. <https://www.fda.gov/food/guidance-documents-regulatory-information-topic-food-and-dietary-supplements/seafood-guidance-documents-regulatory-information> (last updated June 12, 2020). [Link](#).
- U.S. Food and Drug Administration (FDA). *Fish and Fishery Products Hazards and Controls Guidance Fourth Edition*. June 2021. <https://www.fda.gov/food/seafood-guidance-documents-regulatory-information/fish-and-fishery-products-hazards-and-controls>. [Link](#).
- U.S. National Oceanic and Atmospheric Administration (NOAA). *Regulating Aquaculture*. <https://www.fisheries.noaa.gov/regulating-aquaculture> (last updated Oct. 15, 2021). [Link](#).
- Vince J, Haward M. Hybrid Governance in Aquaculture: Certification Schemes and Third-Party Accreditation. *Aquaculture* 2019;507:322-328. [Link](#).
- B. Applications -- ELSI Issues**
- Beveridge MCM, Thilsted SH, Phillips MJ, Metian M, Troell M, Hall SJ. Meeting the Food and Nutrition Needs of the Poor: The Role of Fish and the Opportunities and Challenges Emerging from the Rise of Aquaculture. *Journal of Fish Biology* 2013;83:1067-1084. [Link](#).
- Little DC, Newton RW, Beveridge MCM. Aquaculture: A Rapidly Growing and Significant Source of Sustainable Food? Status, Transitions and Potential. *Proceedings of the Nutrition Society* 2016;75:274-286. [Link](#).
- Liu Y, Monroe WT, Belgodere J, Choi JW, Gutierrez-Wing MT, Tiersch TR. The Emerging Role of Open Technologies for Community-Based Improvement of Cryopreservation and Quality Management for Repository Development in Aquatic Species. *Animal Reproduction Science* 2021. doi:[10.1016/j.anireprosci.2021.106871](https://doi.org/10.1016/j.anireprosci.2021.106871). [Link](#).
- Naylor RL, et al. A 20-Year Retrospective Review of Global Aquaculture. *Nature* 2021;591:551-563. [Link](#).